ATRA Relative Valuation
ATRA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATRA is overvalued; if below, it's undervalued.
Historical Valuation
Atara Biotherapeutics Inc (ATRA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -0.29. The fair price of Atara Biotherapeutics Inc (ATRA) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：14.00
Fair
15.60
PE
1Y
3Y
5Y
Trailing
Forward
8.01
EV/EBITDA
Atara Biotherapeutics Inc. (ATRA) has a current EV/EBITDA of 8.01. The 5-year average EV/EBITDA is -2.39. The thresholds are as follows: Strongly Undervalued below -15.93, Undervalued between -15.93 and -9.16, Fairly Valued between 4.38 and -9.16, Overvalued between 4.38 and 11.15, and Strongly Overvalued above 11.15. The current Forward EV/EBITDA of 8.01 falls within the Overvalued range.
8.47
EV/EBIT
Atara Biotherapeutics Inc. (ATRA) has a current EV/EBIT of 8.47. The 5-year average EV/EBIT is -0.23. The thresholds are as follows: Strongly Undervalued below -7.16, Undervalued between -7.16 and -3.70, Fairly Valued between 3.24 and -3.70, Overvalued between 3.24 and 6.70, and Strongly Overvalued above 6.70. The current Forward EV/EBIT of 8.47 falls within the Strongly Overvalued range.
1.85
PS
Atara Biotherapeutics Inc. (ATRA) has a current PS of 1.85. The 5-year average PS is 13.76. The thresholds are as follows: Strongly Undervalued below -28.93, Undervalued between -28.93 and -7.58, Fairly Valued between 35.11 and -7.58, Overvalued between 35.11 and 56.46, and Strongly Overvalued above 56.46. The current Forward PS of 1.85 falls within the Historic Trend Line -Fairly Valued range.
-2.31
P/OCF
Atara Biotherapeutics Inc. (ATRA) has a current P/OCF of -2.31. The 5-year average P/OCF is -3.67. The thresholds are as follows: Strongly Undervalued below -10.69, Undervalued between -10.69 and -7.18, Fairly Valued between -0.17 and -7.18, Overvalued between -0.17 and 3.34, and Strongly Overvalued above 3.34. The current Forward P/OCF of -2.31 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Atara Biotherapeutics Inc. (ATRA) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.41. The thresholds are as follows: Strongly Undervalued below -6.39, Undervalued between -6.39 and -4.40, Fairly Valued between -0.42 and -4.40, Overvalued between -0.42 and 1.57, and Strongly Overvalued above 1.57. The current Forward P/FCF of 0.00 falls within the Overvalued range.
Atara Biotherapeutics Inc (ATRA) has a current Price-to-Book (P/B) ratio of -2.47. Compared to its 3-year average P/B ratio of 1.82 , the current P/B ratio is approximately -235.43% higher. Relative to its 5-year average P/B ratio of 2.41, the current P/B ratio is about -202.38% higher. Atara Biotherapeutics Inc (ATRA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -180.18%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -119.32% , the current FCF yield is about -100.00% lower.
-2.79
P/B
Median3y
1.82
Median5y
2.41
-77.14
FCF Yield
Median3y
-180.18
Median5y
-119.32
Competitors Valuation Multiple
The average P/S ratio for ATRA's competitors is 0.00, providing a benchmark for relative valuation. Atara Biotherapeutics Inc Corp (ATRA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -91.41%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ATRA increased by 6.69% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -54.51 to -124.62.
The secondary factor is the P/E Change, contributed -30.52%to the performance.
Overall, the performance of ATRA in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Atara Biotherapeutics Inc (ATRA) currently overvalued or undervalued?
What is Atara Biotherapeutics Inc (ATRA) fair value?
How does ATRA's valuation metrics compare to the industry average?
What is the current P/B ratio for Atara Biotherapeutics Inc (ATRA) as of Dec 05 2025?
What is the current FCF Yield for Atara Biotherapeutics Inc (ATRA) as of Dec 05 2025?
What is the current Forward P/E ratio for Atara Biotherapeutics Inc (ATRA) as of Dec 05 2025?